Acute lymphoblastic leukemia cells resistant to CD19 immunotherapies exhibit combined loss of CD19 and CD22 and an enhanced sensitivity to BTK and MEK inhibition. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.